188 related articles for article (PubMed ID: 37240068)
21. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of PD-L1 expression combined with hypoxia-associated immunosuppression in hepatocellular carcinoma.
Qian Y; Su H; Ge Y; Lei K; Li Y; Fan H
Biomark Med; 2022 Apr; 16(6):435-448. PubMed ID: 35212229
[No Abstract] [Full Text] [Related]
23. PD-L1 and Immune Infiltration of m
Lin Y; Yao Y; Wang Y; Wang L; Cui H
Biomed Res Int; 2021; 2021():5516100. PubMed ID: 34055974
[TBL] [Abstract][Full Text] [Related]
24. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
25. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
26. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
27. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K
Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805
[TBL] [Abstract][Full Text] [Related]
28. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
29. Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines.
Qian Q; Wu C; Chen J; Wang W
Biomed Res Int; 2020; 2020():8910183. PubMed ID: 32724815
[TBL] [Abstract][Full Text] [Related]
30. Tumor-derived PD1 and PD-L1 could promote hepatocellular carcinoma growth through autophagy induction in vitro.
Chen Z; Liu S; Xie P; Zhang B; Yu M; Yan J; Jin L; Zhang W; Zhou B; Li X; Xiao Y; Xu Y; Ye Q; Li H; Guo L
Biochem Biophys Res Commun; 2022 May; 605():82-89. PubMed ID: 35316767
[TBL] [Abstract][Full Text] [Related]
31. Pentamethylquercetin Inhibits Hepatocellular Carcinoma Progression and Adipocytes-induced PD-L1 Expression via IFN-γ Signaling.
Li Z; Gao WQ; Wang P; Wang TQ; Xu WC; Zhu XY; Liu H
Curr Cancer Drug Targets; 2020; 20(11):868-874. PubMed ID: 32748749
[TBL] [Abstract][Full Text] [Related]
32. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
33. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
[TBL] [Abstract][Full Text] [Related]
34. The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis.
Yang Y; Chen D; Zhao B; Ren L; Huang R; Feng B; Chen H
Cancer Med; 2023 Apr; 12(8):9282-9292. PubMed ID: 36965092
[TBL] [Abstract][Full Text] [Related]
35. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
Sangro B; Melero I; Wadhawan S; Finn RS; Abou-Alfa GK; Cheng AL; Yau T; Furuse J; Park JW; Boyd Z; Tang HT; Shen Y; Tschaika M; Neely J; El-Khoueiry A
J Hepatol; 2020 Dec; 73(6):1460-1469. PubMed ID: 32710922
[TBL] [Abstract][Full Text] [Related]
36. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1.
Li S; Ji J; Zhang Z; Peng Q; Hao L; Guo Y; Zhou W; Cui Q; Shi X
Mol Cell Biochem; 2020 Dec; 475(1-2):79-91. PubMed ID: 32761300
[TBL] [Abstract][Full Text] [Related]
38. CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
Semaan A; Dietrich D; Bergheim D; Dietrich J; Kalff JC; Branchi V; Matthaei H; Kristiansen G; Fischer HP; Goltz D
Virchows Arch; 2017 Feb; 470(2):185-196. PubMed ID: 27913861
[TBL] [Abstract][Full Text] [Related]
39. Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression.
Lv T; Xiong X; Yan W; Liu M; Xu H; He Q
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688553
[TBL] [Abstract][Full Text] [Related]
40. Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment.
Zhang G
Front Immunol; 2022; 13():975762. PubMed ID: 36189226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
